PrintBio
Private Company
Funding information not available
Overview
PrintBio is a private, US-based biotech firm founded in 2021, operating at the intersection of synthetic biology, regenerative medicine, and advanced manufacturing. The company has developed a proprietary 3D-bioprinting platform initially applied to create its first commercial products: programmable, bioresorbable surgical meshes. Led by a seasoned biotech entrepreneur and surgeon, Dr. Kevin Slawin, PrintBio aims to evolve from surgical mesh into the broader field of on-demand, living tissue and organ implants. Its strategy combines near-term revenue generation from surgical products with a long-term vision for disruptive regenerative therapies.
Technology Platform
Proprietary 3D-bioprinting platform integrated with advanced material science, enabling the creation of programmable, bioresorbable surgical meshes with tunable mechanical properties (MetaDirectional Flex™) and serving as a foundation for future living tissue implants.
Opportunities
Risk Factors
Competitive Landscape
In surgical meshes, PrintBio competes with large medical device companies (e.g., BD, Medtronic, J&J) offering traditional and biologic meshes, as well as smaller innovators in resorbable materials. In the broader bioprinting space, it faces competition from other bioprinting firms (e.g., Organovo, CELLINK) and academic consortia, all pursuing tissue engineering applications, though few have commercial surgical products.